In Vitro Bioequivalence Approach for a Locally Acting Gastrointestinal Drug: Lanthanum Carbonate
- 4 January 2013
- journal article
- review article
- Published by American Chemical Society (ACS) in Molecular Pharmaceutics
- Vol. 10 (2) , 544-550
Abstract
A conventional human pharmacokinetic (PK) in vivo study is often considered as the “gold standard” to determine bioequivalence (BE) of drug products. However, this BE approach is not always applicable to the products not intended to be delivered into the systemic circulation. For locally acting gastrointestinal (GI) products, well designed in vitro approaches might be more practical in that they are able not only to qualitatively predict the presence of the active substance at the site of action but also to specifically assess the performance of the active substance. For example, lanthanum carbonate chewable tablet, a locally acting GI phosphate binder when orally administrated, can release free lanthanum ions in the acid environment of the upper GI tract. The lanthanum ions directly reach the site of action to bind with dietary phosphate released from food to form highly insoluble lanthanum–phosphate complexes. This prevents the absorption of phosphate consequently reducing the serum phosphate. Thus, using a conventional PK approach to demonstrate BE is meaningless since plasma levels are not relevant for local efficacy in the GI tract. Additionally the bioavailability of lanthanum carbonate is less than 0.002%, and therefore, the PK approach is not feasible. Therefore, an alternative assessment method is required. This paper presents an in vitro approach that can be used in lieu of PK or clinical studies to determine the BE of lanthanum carbonate chewable tablets. It is hoped that this information can be used to finalize an in vitro guidance for BE studies of lanthanum carbonate chewable tablets as well as to assist with “in vivo” biowaiver decision making. The scientific information might be useful to the pharmaceutical industry for the purpose of planning and designing future BE studies.Keywords
This publication has 13 references indexed in Scilit:
- Development and validation of an ion chromatography method for the determination of phosphate-binding of lanthanum carbonateJournal of Pharmaceutical and Biomedical Analysis, 2010
- Therapeutic use of the phosphate binder lanthanum carbonateExpert Opinion on Drug Metabolism & Toxicology, 2008
- In Vitro Studies are Sometimes Better than Conventional Human Pharmacokinetic In Vivo Studies in Assessing Bioequivalence of Immediate-Release Solid Oral Dosage FormsThe AAPS Journal, 2008
- FDA Critical Path Initiatives: Opportunities for Generic Drug DevelopmentThe AAPS Journal, 2008
- Clinical Pharmacokinetics of the Phosphate Binder Lanthanum CarbonateClinical Pharmacokinetics, 2008
- Bioequivalence Approaches for Highly Variable Drugs and Drug ProductsPharmaceutical Research, 2007
- Absolute Bioavailability and Disposition of Lanthanum in Healthy Human Subjects Administered Lanthanum CarbonateThe Journal of Clinical Pharmacology, 2006
- Lanthanum carbonate: a new phosphate binderCurrent Opinion in Nephrology and Hypertension, 2004
- Bioavailability and Bioequivalence: An FDA Regulatory OverviewPharmaceutical Research, 2001
- Understanding the Dose-Effect RelationshipClinical Pharmacokinetics, 1981